热门站点| 世界资料网 | 专利资料网 | 世界资料网论坛
收藏本站| 设为首页| 首页

长沙市人民政府关于印发《长沙市市属特困企业职工医疗救助暂行办法》的通知

作者:法律资料网 时间:2024-07-12 18:19:17  浏览:9853   来源:法律资料网
下载地址: 点击此处下载

长沙市人民政府关于印发《长沙市市属特困企业职工医疗救助暂行办法》的通知

湖南省长沙市人民政府


长沙市人民政府关于印发《长沙市市属特困企业职工医疗救助暂行办法》的通知

长政发〔2004〕24号

各区、县(市)人民政府,市直机关各单位:
现将《长沙市市属特困企业职工医疗救助暂行办法》印发给你们,请认真遵照执行。


长沙市人民政府

二00四年七月十六日

长沙市市属特困企业职工医疗救助暂行办法

第一条 为完善社会保障体系,对市属特困企业职工(含退休人员,下同)给予医疗救助,制定本办法。
第二条 医疗救助实行“统一管理,指定医院,定额救助,财政负担,社会支持”的原则。
第三条 市属特困企业职工是指:
(一)完全无缴费能力的严重亏损、停产、半停产的企业职工及退休人员;
(二)符合依法破产条件但未完成破产程序且未参加医疗保险的企业职工及退休人员;
(三)因注销关闭无管理单位而未参加医疗保险的企业退休人员(以下简称无管理单位的退休人员)。
第四条 市劳动和社会保障局负责实施本办法的有关具体工作,市医疗保险管理服务中心负责经办医疗救助工作。
财政、卫生、民政等有关职能部门配合做好本办法的实施工作。
第五条 建立医疗救助基金,由市财政按每人每年180元的标准拨付,设立专项账户,单独建账管理,专款专用,任何单位和个人不得挤占、截留、挪用。同时建立超标准救助准备金,由市财政按医疗救助基金总额的20%另行拨付。
第六条 要求享受医疗救助的市属特困企业应由本企业职工代表大会审议通过,并向市医疗保险管理服务中心提出申请。
第七条 市属特困企业申请医疗救助须提交下列材料:
(一)《长沙市市属特困企业医疗救助申请审批表》;
(二)市属特困企业申请医疗救助的书面报告;
(三)企业职工代表大会审议通过的申请医疗救助的决议;
(四)连续三年的《长沙市企业会计报表——资产负债表》;
(五)连续三年的《长沙市企业会计报表——资产损益表》;
(六)有关部门规定的其他材料。
符合破产条件但未完成破产程序的企业还须提交符合依法破产条件的相关材料。
第八条 市属特困企业医疗救助申请经市劳动保障行政部门批准后,携带本企业职工花名册到市医疗保险管理服务中心办理相关手续,领取《长沙市特困企业职工医疗救助证》(以下简称《救助证》)。
第九条 无管理单位的退休人员申请医疗救助,按以下程序办理:
(一)向户籍所在街道劳动保障服务机构提出申请。
(二)申请医疗救助应提供下列材料:1、本人居民身份证、退休证、领取养老金证;2、原企业注销关闭的有关证明;3、《注销关闭企业退休人员医疗救助申请审批表》;4、有关部门规定的其他证明材料。
(三)街道劳动保障服务机构初审后,报市医疗保险管理服务中心审核,由市劳动和社会保障局批准发放《救助证》。
第十条 市属特困企业职工享受医疗救助待遇,从批准之日起执行。
第十一条 市属特困企业职工因病住院,其符合基本医疗保险药品目录、诊疗项目、医疗服务设施标准(以下简称“三个目录”)规定范围内的医疗费用,享受医疗救助。门诊医疗费用不享受医疗救助。
第十二条 医疗救助实行指定医疗机构制度。
所指定的医疗机构必须是已承诺对市属特困企业职工医疗费用实行适度减免,并经市劳动和社会保障局和市卫生局确定的医疗机构。
第十三条 市属特困企业职工享受医疗救助待遇,应携带本人居民身份证和《救助证》,到指定医疗机构就医,按规定属医疗救助基金支付的医疗费用,由市医疗保险管理服务中心与指定医疗机构结算,其余部分由市属特困企业职工与指定医疗机构结算。在非指定医疗机构就医不享受医疗救助待遇。
第十四条 市属特困企业职工就医符合基本医疗保险“三个目录”的住院医疗费用,按40%的标准给予救助。在一个医疗保险结算年度内,每人累计救助额不超过2000元。
第十五条 医疗救助实行年审制度,经审查不符合条件的,停止享受医疗救助。
第十六条 凡享受医疗救助待遇的市属特困企业职工在一个医疗保险结算年度内,其符合基本医疗保险“三个目录”的住院医疗费用在1万元以上的,由企业或街道劳动保障服务机构专题向市劳动和社会保障局报告(附有关证明材料),在超标准救助准备金中适当救助。具体办法由市劳动和社会保障局商市财政局制
定。
第十七条 市属特困企业职工下列情形就医所发生的住院医疗费用,不享受医疗救助:
(一)自杀、自残、斗殴、酗酒和吸毒;
(二)交通、医疗事故;
(三)其他违法行为导致病、伤、残的。
第十八条 本办法自2004年8月1日起施行。

下载地址: 点击此处下载

放射性药品管理办法(附英文)

国务院


放射性药品管理办法(附英文)

1989年1月13日,国务院

第一章 总 则
第一条 为了加强放射性药品的管理,根据《中华人民共和国药品管理法》(以下称《药品管理法》)的规定,制定本办法。
第二条 放射性药品是指用于临床诊断或者治疗的放射性核素制剂或者其标记药物。
第三条 凡在中华人民共和国领域内进行放射性药品的研究、生产、经营、运输、使用、检验、监督管理的单位和个人都必须遵守本办法。
第四条 卫生部主管全国放射性药品监督管理工作。能源部主管放射性药品生产、经营管理工作。

第二章 放射性新药的研制、临床研究和审批
第五条 放射性新药是指我国首次生产的放射性药品。药品研制单位的放射性新药年度研制计划,应当报送能源部备案,并报所在地的省、自治区、直辖市卫生行政部门,经卫生行政部门汇总后,报卫生部备案。
第六条 放射性新药的研制内容,包括工艺路线、质量标准、临床前药理及临床研究。研制单位在制订新药工艺路线的同时,必须研究该药的理化性能、纯度(包括核素纯度)及检验方法、药理、毒理、动物药代动力学、放射性比活度、剂量、剂型、稳定性等。
研制单位对放射免疫分析药盒必须进行可测限度、范围、待异性、准确度、精密度、稳定性等方法学的研究。
放射性新药的分类,按新药审批办法的规定办理。
第七条 研制单位研制的放射性新药,在进行临床试验或者验证前,应当向卫生部提出申请,按新药审批办法的规定报送资料及样品,经卫生部审批同意后,在卫生部指定的医院进行临床研究。
第八条 研制单位在放射性新药临床研究结束后,向卫生部提出申请,经卫生部审核批准,发给新药证书。卫生部在审核批准时,应当征求能源部的意见。
第九条 放射性新药投入生产,需由生产单位或者取得放射性药品生产许可证的研制单位,凭新药证书(副本)向卫生部提出生产该药的申请,并提供样品,由卫生部审核发给批准文号。

第三章 放射性药品的生产、经营和进出口
第十条 放射性药品生产、经营企业,必须向能源部报送年度生产、经营计划,并抄报卫生部。
第十一条 国家根据需要,对放射性药品实行合理布局,定点生产。申请开办放射性药品生产、经营的企业,应征得能源部的同意后,方可按照有关规定办理筹建手续。
第十二条 开办放射性药品生产、经营企业,必须具备《药品管理法》第五条规定的条件,符合国家的放射卫生防护基本标准,并履行环境影响报告的审批手续,经能源部审查同意,卫生部审核批准后,由所在省、自治区、直辖市卫生行政部门发给《放射性药品生产企业许可证》、《派湫砸┢肪笠敌砜芍ぁ贰N扌砜芍さ纳⒕笠担宦刹蛔忌⑾鄯派湫砸┢贰?
第十三条 《放射性药品生产企业许可证》、《放射性药品经营企业许可证》的有效期为五年,期满前六个月,放射性药品生产、经营企业应当分别向原发证的卫生行政部门重新提出申请,按第十二条审批程序批准后,换发新证。
第十四条 放射性药品生产企业生产已有国家标准的放射性药品,必须经卫生部征求能源部意见后审核批准,并发给批准文号。凡是改变卫生部已批准的生产工艺路线和药品标准的,生产单位必须按原报批程序经卫生部批准后方能生产。
第十五条 放射性药品生产、经营企业,必须配备与生产、经营放射性药品相适应的专业技术人员。具有安全、防护和废气、废物、废水处理等设施。并建立严格的质量管理制度。
第十六条 放射性药品生产、经营企业,必须建立质量检验机构,严格实行生产全过程的质量控制和检验。产品出厂前,须经质量检验。符合国家药品标准的产品方可出厂,不符合标准的产品一律不准出厂。
经卫生部审核批准的含有短半衰期放射性核素的药品,可以边检验边出厂,但发现质量不符合国家药品标准时,该药品的生产企业应当立即停止生产、销售,并立即通知使用单位停止使用,同时报告卫生部和能源部。
第十七条 放射性药品的生产、供销业务由能源部统一管理。放射性药品的生产、经营单位和医疗单位凭省、自治区、直辖市卫生行政部门发给的《放射性药品生产企业许可证》、《放射性药品经营企业许可证》,医疗单位凭省、自治区、直辖市公安、环保和卫生行政部门联合发给的《放射性药品使用许可证》,申请办理订货。
第十八条 放射性药品的进出口业务,由对外经济贸易部指定的单位,按照国家有关对外贸易的规定办理。
进出口放射性药品,应当报卫生部审批同意后,方得办理进出口手续。
进口的放射性药品品种,必须符合我国的药品标准或者其他药用要求。
第十九条 进口放射性药品,必须经中国药品生物制品检定所或者卫生部授权的药品检验所抽样检验;检验合格的,方准进口。
对于经卫生部审核批准的短半衰期放射性核素的药品,在保证安全使用的情况下,可以采取边进口检验,边投入使用的办法。进口检验单位发现药品质量不符合要求时,应当立即通知使用单位停止使用,并报告卫生部和能源部。

第四章 放射性药品的包装和运输
第二十条 放射性药品的包装必须安全实用,符合放射性药品质量要求,具有与放射性剂量相适应的防护装置。包装必须分内包装和外包装两部分,外包装必须贴有商标、标签、说明书和放射性药品标志,内包装必须贴有标签。
标签必须注明药品品名、放射性比活度、装量。
说明书除注明前款内容外,还须注明生产单位、批准文号、批号、主要成份、出厂日期、放射性核素半衰期、适应症、用法、用量、禁忌症、有效期和注意事项等。
第二十一条 放射性药品的运输,按国家运输、邮政等部门制订的有关规定执行。
严禁任何单位和个人随身携带放射性药品乘坐公共交通运输工具。
第二十二条 医疗单位设置核医学科、室(同位素室),必须配备与其医疗任务相适应的并经核医学枝术培训的技术人员。非核医学专业技术人员未经培训,不得从事放射性药品使用工作。
第二十三条 医疗单位使用放射性药品,必须符合国家放射性同位素卫生防护管理的有关规定。所在地的省、自治区、直辖市的公安、环保和卫生行政部门,应当根据医疗单位核医疗技术人员的水平、设备条件,核发相应等级的《放射性药品使用许可证》,无许可证的医疗单位不得临床使用放射性药品。
《放射性药品使用许可证》有效期为五年,期满前六个月,医疗单位应当向原发证的行政部门重新提出申请,经审核批准后,换发新证。
第二十四条 持有《放射性药品使用许可证》的医疗单位,在研究配制放射性制剂并进行临床验证前,应当根据放射性药品的持点,提出该制剂的药理、毒性等资料,由省、自治区、直辖市卫生行政部门批准,并报卫生部备案。该制剂只限本单位内使用。
第二十五条 持有《放射性药品使用许可证》的医疗单位,必须负责对使用的放射性药品进行临床质量检验,收集药品不良反应等项工作,并定期向所在地卫生行政部门报告。由省、自治区、直辖市卫生行政部门汇总后报卫生部。
第二十六条 放射性药品使用后的废物(包括患者排出物),必须按国家有关规定妥善处置。

第五章 放射性药品标准和检验
第二十七条 放射性药品的国家标准,由卫生部药典委员会负责制定和修订,报卫生部审批颁发。
第二十八条 放射性药品的检验由中国药品生物制品检定所或者卫生部授权的药品检验所承担。

第六章 附 则
第二十九条 对违反本办法规定的单位或者个人,由县以上卫生行政部门,按照《药品管理法》和有关法规的规定处罚。
第三十条 本办法由卫生部负责解释。
第三十一条 本办法自发布之日起施行。

MEASURES FOR THE CONTROL OF RADIOACTIVE DRUGS

Important Notice: (注意事项)
英文本源自中华人民共和国务院法制局编译, 中国法制出版社出版的《中华人民
共和国涉外法规汇编》(1991年7月版).
当发生歧意时, 应以法律法规颁布单位发布的中文原文为准.
This English document is coming from the "LAWS AND REGULATIONS OF THE
PEOPLE'S REPUBLIC OF CHINA GOVERNING FOREIGN-RELATED MATTERS" (1991.7)
which is compiled by the Brueau of Legislative Affairs of the State
Council of the People's Republic of China, and is published by the China
Legal System Publishing House.
In case of discrepancy, the original version in Chinese shall prevail.

Whole Document (法规全文)
MEASURES FOR THE CONTROL OF RADIOACTIVE DRUGS
(Promulgated by Decree No. 25 of the State Council of the People's
Republic of China on January 13, 1989 and effective as of the date of
promulgation)

Chapter I General Provisions
Article 1
These Measures are formulated to strengthen the control of radioactive
drugs in accordance with Pharmaceutical Administration Law of the People's
Republic of China (hereinafter referred to as the Pharmaceutical
Administration Law)
Article 2
"Radioactive drugs" refer to any forms of radionuclide or their tagged
drugs that are used for clinical diagnosis or in radiotherapy.
Article 3
All units or individuals in the People's Republic of China are required to
abide by these Measures when they are engaged in research work,
production, business, transportation, consumption, examination,
supervision and administration work related to radioactive drugs.
Article 4
The Ministry of Public Health is in charge of the supervisory and
administrative work of radioactive drugs while the Ministry of Energy is
in charge of the administration work concerning the production and sale of
radioactive drugs.

Chapter II Examination and Approval for the Development and Cli- nical Research of New Radioactive Drugs
Article 5
"New radioactive drugs" refer to those radioactive drugs that are made in
China for the first time. The annual plan of any drug research units for
the development of new radioactive drugs must be submitted to both the
Ministry of Energy for the record and to the health administration
department at the provincial, autonomous regional or municipal (directly
under the Central Government) level. Then an itemized plan made by the
latter shall be presented to the Ministry of Public Health for the record.
Article 6
The development of a new kind of radioactive drug includes the research
work in its technological process, quality requirements,
preclinicopharmacological study and clinical study;
The research unit, when designing the technological process for a new
drug, must study the physical and chemical properties, purity (including
pureness of radionuclide), testing method, pharmacology, toxicity, nuclein
animal dynamics, radiospecific activity, dosage, pharmaceutical forms and
stability of that radioactive drug. Furthermore, the research unit must
make a study of radio-immunity analysis container with respect to its
scalability, range, specificity, accuracy, precision and stability.
New kinds of radioactive drugs shall be classified in accordance with the
provisions for the examination and approval of new pharmaceuticals.
Article 7
Before the newly developed radioactive drug is put to clinical test or
verification, an application together with the data and sample must be
submitted to the Ministry of Public Health in accordance with the
provisions for the examination and approval of new pharmaceuticals.
The newly developed radioactive drug may be used for clinical study at an
appointed hospital only after its application has been examined and
approved by the Ministry of Public Health.
Article 8
After completion of clinical study of a newly developed radioactive drug,
the research unit must submit an application to the Ministry of Public
Health for examination and approval.
The latter shall consult the Ministry of Energy before granting a New Drug
License.
Article 9
Before a newly developed radioactive drug is put to production, the
production unit or the research unit that holds a license for the
production of radioactive drugs must submit an application together with a
copy of New Drug License and sample to the Ministry of Public Health.
After examination and verification, the Ministry of Public Health shall
issue them document of approval.

Chapter III The Production, Sales, Import and Export of Radio- active Drugs
Article 10
The enterprises that produce or sell radioactive drugs are required to
submit their production plan and business plan to the Ministry of Energy
and a duplicate to the Ministry of Public Health.
Article 11
The State shall, according to the actual conditions, make sure that
radioactive drugs be produced at designated pharmaceutical factories which
shall be located rationally over the country. Applications for the setting
up of any enterprises to produce or sell radioactive drugs must be
approved by the Ministry of Energy before the preparations start in
accordance with related provisions.
Article 12
Requirements for the setting up of enterprises to produce or sell
radioactive drugs are that they must have the necessary conditions as
stipulated in Article 5 of the Pharmaceutical Administration Law and that
they must meet the essential standard of radio hygiene protection set by
the State. They are also required to submit a report on environment impact
to the Ministry of Energy and the Ministry of Public Health for
examination and approval and then the health administration department in
their province, autonomous region or municipality directly under the
Central Government shall issue them "License for the Production Enterprise
of Radioactive Drugs", "License for the Business Enterprise of Radioactive
Drugs". No enterprises without the license shall be permitted to engage in
the production or sale of radioactive drugs.
Article 13
The term of validity of "License for the Production Enterprise of
Radioactive Drugs" and "License for the Business Enterprise of Radioactive
Drugs" is five years. If needed, the enterprises engaged in the production
or sale of radioactive drugs shall make a new application six months
before the expiration to the health administration department which shall,
in accordance with Article 12 of these Provisions, issue them a new
license.
Article 14
Before an approved pharmaceutical enterprise produces radioactive drugs
with specifications already set by the State, it must forward an
application which has to be examined and approved by the Ministry of
Public Health in conjunction with the Ministry of Energy. If any changes
in the technological process and specifications of the drugs previously
approved by the Ministry of Public Health are to be made, the
pharmaceutical factory shall be required to go through the same procedures
for approval.
Article 15
The production and business enterprises of radioactive drugs are required
to employ technical personnel who are qualified for the work and to have
safety and protection facilities as well as waste gas, liquid and material
disposal facilities. They must also have a strict quality control system.
Article 16
The production and business enterprises of radioactive drugs are required
to set up quality inspection offices. The entire process of production
must be put under strict qualify control and inspection.
All radioactive drugs are subject to quality testing. Only the products
that meet the State pharmaceutical standard shall be allowed to be shipped
out from the factories. Products that are not up to the standard are not
allowed out of the factory. As for the drugs with short half-life
radionuclide previously approved by the Ministry of Public Health, they
may be shipped out from the factory while having sample testing. If the
drugs are found to be below the State pharmaceutical standard, the factory
must stop the production and sale of the drugs immediately and inform
consuming units to stop using the drugs without delay. A report about the
case must be submitted to both the Ministry of Public Health and the
Ministry of Energy.
Article 17
The production, supply and sale of radioactive drugs are under the unified
administration of the Ministry of Energy.
When ordering these stuff, the pharmaceutical factory must furnish a
License for the Production Enterprise of Radioactive Drugs while the
business unit must present a License for the Business Enterprise of
Radioactive Drugs issued by the health administration department at the
provincial, autonomous regional or municipal (directly under the Central
Government) level. As for the medical treatment unit, they must order
these drugs with a License for the Use of Radioactive Drugs jointly issued
by the public security department, the environment protection department
and health administration department at the provincial, autonomous
regional or the municipal (directly under the Central Government) level.
Article 18
The import and export business of radioactive drugs shall be handled by
the units appointed by the Ministry of Foreign Economic Relations and
Trade in accordance with the State provisions related to foreign trade.
Prior to the import or export of radioactive drugs, an application must be
made and be examined and approved by the Ministry of Public Health.
Imported radioactive drugs are required to meet the State standards for
pharmaceuticals or other medical requirements.
Article 19
Imported radioactive drugs are subject to sample examination by the State
Administration for the Inspection and Testing of Pharmaceuticals and
Biological Products or by an inspection and testing institution of
pharmaceuticals authorized by the Ministry of Public Health. Only those
drugs that have met the State standards are allowed to be imported. As for
the drugs with short half-life radionuclide previously approved by the
Ministry of Public Health, they may be put to use upon being shipped in
while having import inspection. If the import inspection unit finds the
quality of imported drugs not up to the standard, they must inform the
consuming units promptly to stop using the drugs. A report about the
quality problem must be submitted to both the Ministry of Public Health
and the Ministry of Energy.

Chapter IV The Packaging and Shipment of Radioactive Drugs
Article 20
The packaging of radioactive drugs must be safe and reliable, and up to
the standards for the quality requirements of radioactive drug. There must
be protection devices that will match different radio dosages. The
packaging is required to consist of packing and inner packaging. There
must be trade mark, label, specifications and marker of radioactive drugs
on the packing and a label on the inner packaging. On the label there must
be name of the drug, radiospecific activity and packings.
The specifications must indicate the name of the producer, license number,
batch number, main composition, date of manufacture, half-life of
radionuclide, indications, administration, dosage, contraindication,
expiry date and precautions in addition to name of the drug, radioapecific
activity and packings.
Article 21
The shipment of radioactive drugs shall be handled in accordance with the
rules formulated by the State transportation and postal departments. No
unit or person shall be allowed to carry along radioactive drugs on any
means of public transportation.

Chapter V The Use of Radioactive Drugs
Article 22
If a medical treatment unit desires to set up a radiologic department or a
radioisotope department, it is required to employ technical personnel who
are qualified for radiotherapeutic work after special technical training.
Without prior technical training no personnel shall be allowed to use the
drugs in radiotherapy.
Article 23
When a medical treatment unit uses radioactive drugs, it must observe the
rules formulated by the State concerning radioisotope hygiene and
protection. The health administration department, the public security
department and the environment protection department at provincial,
autonomous regional or municipal (directly under the Central Government)
level shall issue a certain grade of License for the Use of Radioactive
Drugs according to technical skill and professional level of the
radiological personnel and equipment of the medical treatment unit. No
medical treatment unit without a license is allowed to use radioactive
drugs clinically.
The term of validity of a License for the Use of Radioactive Drugs is 5
years. If needed, the medical treatment unit must make a new application 6
months before the expiration of its license to the health administration
department which, after examination and verification shall issue it a new
license.
Article 24
Before a medical treatment unit holding a License for the Use of
Radioactive Drugs starts the preparation of any forms of radioactive drug
for clinical use, it is required to submit an application with the data
concerning pharmacology and toxicity of the radioactive drug, according to
the characteristics of the radioactive drug, to the health administration
department at the provincial, autonomous regional or municipal (directly
under the Central Government) level for approval and to the Ministry of
Public Health for the record. That form of radioactive drug can be used
only in the medical treatment unit.
Article 25
The medical treatment units that hold a License for the Use of Radioactive
Drugs are required to conduct clinical quality testing of the radioactive
drugs and find out their undesirable reactions and submit regular reports
to the health administration department. The health administration
department at the provincial, autonomous regional or municipal (directly
under the Central Government) level shall then present an itemized report
to the Ministry of Public Health.
Article 26
Waste material of radioactive drugs (including patients' excrement) must
be properly disposed of in accordance with the State regulations.

Chapter VI The Standards for Radioactive Drugs and Their Testing
Article 27
The Pharmacopoeia Commission under the Ministry of Public Health is
entrusted to formulate and revise the State standards for radioactive
drugs and then submit it to the Ministry of Public Health for examination
and approval before it is promulgated.
Article 28
The State Administration for the Inspection and Testing of Pharmaceuticals
and Biological Products or an inspection and testing institution of
pharmaceuticals authorized by the Ministry of Public Health is entrusted
to inspect and examine radioactive drugs.

Chapter VII Supplementary Provisions
Article 29
Any unit or individual that violates these Measures shall be penalized by
the health administration department at or above the county level in
accordance with the Pharmaceutical Administration Law and other rules and
regulations.
Article 30
The right to interpret these Measures resides in the Ministry of Public
Health.
Article 31
These Measures shall go into effect as of the date of promulgation.


大连市道路大型物件运输管理办法

辽宁省大连市人民政府


大连市道路大型物件运输管理办法
大连市人民政府




第一条 为加强道路大型物件运输管理,确保运输安全,提高社会效益,根据《辽宁省道路运输管理条例》及国家有关规定,制定本办法。
第二条 本办法所称大型物件,是指货物外形尺寸长度在14米以上、宽度在3.5米以上、高度在3米以上的货物,或者重量在20吨以上的单体货物或不解体的成组(捆)货物。
第三条 凡在大连市行政区域内,设立大型物件运输企业和起运经道路运输的大型物件的单位和个人,均应遵守本办法。
第四条 大连市交通局是本市道路大型物件运输业的主管部门,其所属的大连市公路运输管理处(以下简称运管处)具体负责道路大型物件的运输管理工作。
第五条 大型物件按其外形尺寸和重量(含包装和支承架)分成四级:
(一)一级大型物件是指符合长度大于(含本数,下同)14米小于(不含本数,下同)20米;宽度大于3.5米小于4.5米;高度大于3米小于3.8米;重量大于20吨小于100吨条件之一的大型物件。
(二)二级大型物件是指符合长度大于20米小于30米;宽度大于4.5米小于5.5米;高度大于3.8米小于4.4米;重量大于100吨小于200吨条件之一的大型物件。
(三)三级大型物件是指符合长度大于30米小于40米;宽度大于5.5米小于6米;高度大于4.4米小于5米;重量大于200吨小于300吨条件之一的大型物件。
(四)四级大型物件是指符合长度大于40米;宽度大于6米;高度大于5米;重量大于300吨条件之一的大型物件。
第六条 道路大型物件运输业户,按其设备、人员等条件,分为四类:
一类 能承运一级大型物件;
二类 能承运一、二级大型物件;
三类 能承运一、二、三级大型物件;
四类 能承运一、二、三、四级大型物件。
第七条 设立道路大型物件运输企业,应具备下列条件:
(一)有完整的企业章程;
(二)有健全的组织机构、固定的营业场所;
(三)有经过业务和技术考核并取得合格证的管理人员和驾驶人员;
(四)有符合规定的专用汽车、停车场地;
(五)有与所经营业务相适应的资金,最低注册资金为100万元人民币。
第八条 申请设立道路大型物件运输企业(含兼营)的,应按下列规定办理审批手续:
(一)申请设立第一、二、三类国内道路大型物件运输企业,应向企业所在地道路运输管理部门提出申请,经市运管处审核并核定运输类别后,报市交通行政主管部门审批。
(二)申请设立第四类国内大型物件运输企业,应向企业所在地道路运输管理部门提出申请,经市交通行政主管部门审核后,报省交通行政主管部门审批。
(三)申请设立外商投资道路大型物件运输企业,可直接向市运管处提出申请,经市交通行政主管部门审核后,按规定报国家或省交通行政主管部门审批。
第九条 经批准设立的道路大型物件运输企业,应持审批部门核发的《公路运输经营许可证》,分别到工商行政管理部门、税务部门办理营业执照、税务登记手续,经市运管处核定营运车辆,领取《道路运输证》后方可从事道路大型物件的运输。
第十条 道路大型物件运输企业变更企业名称、地址、隶属关系、经营规模、经营类别、经济性质的,须按开业审批程序办理有关手续;要求歇业或停业的,应在歇业或停业前三十天内向市运管处提交申请报告。
第十一条 道路大型物件运输采用公开招标的形式确定承运企业。招标活动由市运管处责成大型物件运输招标管理中心(以下简称招标中心)组织实施。
第十二条 道路大型物件运输招标按下列程序办理:
(一)大型物件托运人应在货物起运10日前向招标中心登记,申报货物的品名、规格、重量、尺寸、颜色、数量、起运地、止运地和收货人及运输要求等;
(二)招标中心根据托运人要求编制招标书,向社会公告,并在托运人登记申报后5日内组织招标;
(三)投标的运输企业(含托运人推荐的承运人、外埠运输企业)应在招标日的2天前,向招标中心申请投标,并接受市运管处的资质审查。
(四)经市运管处审查合格的运输企业,向招标中心缴纳1000元押金后参加投标。未中标者在招标结束后、中标者在大型物件起运前,由招标中心退还押金;
(五)中标的运输企业与托运人,在招标中心的指导下签订运输合同;
(六)市运管处凭运输合同对承运大型物件的车辆核发《大连市大型物件运输准运证》,并核发大型物件运输专用信号旗和标志灯。承运人应凭证运输。
第十三条 中标承运人在大型物件起运前,应勘察作业现场和运输路线,熟悉沿途道路、桥涵和线路状况,做好清障及加固的准备工作,并根据托运人的要求运输。不得将大型物件转包给其他业户承运。
第十四条 装卸大型物件由承运人负责的,承运人应检查车辆装卸设备及工具,保证其处于良好的技术状况。托运人自理装卸的,承运人应监装监卸,防止发生运输事故。
第十五条 承运人运输大型物件要通过大连市区的,须持本单位的介绍信、《车辆行驶证》、《大连市大型物件运输准运证》向市公安局交警支队申报运输时间和运输路线,领取《超限运输通行证》。按批准后指定路线行驶。
超高、超长、超重车辆在城市道路上行驶的,应事先征得市政工程行政主管部门同意。
第十六条 装载大型物件的车辆,白天行车应悬挂标志旗;夜晚行车和停车休息时还应装置标志灯。
标志旗的使用方法为:在运输过程中,分别竖于牵引车辆前方两侧和挂车装载物件上的最宽部位两端。如果挂车装载物件的长度超过挂车尾部,需在物件末端的最高点设标志旗。
标志灯的使用方法为:在挂车装载物件的最宽部位两端和超过挂车尾部的末端装设。
第十七条 道路大型物件运输企业,对市人民政府确定为抢险、救灾等紧急运输任务,应实行责任运输,在市交通行政主管部门的统一调度下,及时安排运输车辆,保证运输任务的完成。
第十八条 大型物件运输运价由承运人、托运人参照《辽宁省汽车货物运价规定》,通过招标形式协商议定。
第十九条 违反本办法,由交通行政主管部门按下列规定予以处罚:
(一)未经批准从事大型物件运输的,对承运人处以3000元以上5000元以下罚款;
(二)超越批准类别承运大型物件的,对承运人处以2000元以上3000元以下罚款;
(三)不按规定接受年度审验、未按规定装置大型物件运输专用标志及营业性标志牌的,每车次处300元以上500元以下罚款;
(四)承运人、托运人或货运代理经营人未经招标擅自承运和托运大型物件的,对双方分别处以1000元以上2000元以下罚款。
第二十条 违反本办法,涉及物价、工商、税务、公安、城建等部门管理权限的,由上述部门依法予以处罚。
第二十一条 实施行政处罚,应按照《中华人民共和国行政处罚法》有关规定执行,罚款全部上缴同级财政。
第二十二条 当事人对行政处罚不服的,可依法申请行政复议或提起行政诉讼。逾期不申请行政复议或者不起诉,又不履行行政处罚决定的,由作出处罚决定的行政机关申请人民法院强制执行。
第二十三条 道路大型物件运输管理人员滥用职权、徇私舞弊、玩忽职守的,由其所在单位或上级主管部门给予行政处分;构成犯罪的,由司法机关依法追究刑事责任。
第二十四条 本办法由大连市交通局负责解释。
第二十五条 本办法自发布之日起施行。



1998年4月29日

版权声明:所有资料均为作者提供或网友推荐收集整理而来,仅供爱好者学习和研究使用,版权归原作者所有。
如本站内容有侵犯您的合法权益,请和我们取得联系,我们将立即改正或删除。
京ICP备14017250号-1